- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04834791
Letrozole Versus Gonadotropins in Clomiphene Citrate Resistance
Letrozole Versus Gonadotropins for Ovulation Induction in Clomiphene Citrate Resistance: A Randomized Controlled Study
Study Overview
Status
Intervention / Treatment
Detailed Description
This study included 70 patients enrolled according inclusion and exclusion criteria. The inclusion criteria were (a) Infertility lasting one year or more in presence of regular intercourse, (b) Patients' age between 20-35years (c) Normal semen analysis according to WHO 2010 (d) Patent fallopian tubes (e) Normal prolactin and TSH. (e) Anovulatory cycles confirmed by mid-luteal progesterone ≤ 3 ng/ml and (f) Clomiphene citrate resistance for 3 cycles of 150mg. Exclusion Criteria were (a) Any hormonal disturbances eg. hyperprolactinemia, (b) Immunological causes of infertility, (c) Coital errors, (d) Metabolic disorders and (e) Poor patient compliance.
Sample size calculation: The minimum sample size calculated using Epi info program version 7 for unmatched case control study; 80% power and 95% Confidence interval was 22 for each group. For better accuracy and validity of results the sample size was increased by 10%=3 in each group. The total number of cases was 50 and 25 for each group.
Randomization and allocation: It was a prospective quesi-randomization. Based on the attendance order, patients with odd numbers were considered group I (Letrozole group) and those with even numbers were considered group II (Gonadotropin group). Allocation was equal 1:1.
Intervention:
Group I (Letrozole Group n=25): These patients were treated with letrozole (Femara®, Novartis New York, NY, USA) in a dose 2.5 mg (one tablet daily) orally began on the 3rd day to the 7th day of the cycle. If ovulation is not achieved dose is increased by 2.5 mg in next cycle till 3 cycles. If hyperstimulation occurred, the cycle was cancelled and the patients were excluded from the study.
Group II (Gonadotropin Group n=25) These patients were given urofollitropin (fostimon ®, IBSA, Lugano, Switzerland) in a dose of 75 IU/mL I.M from day 3rd to day 7th of the cycle beginning by one ampoule per day and the dose had been modulated according to response. If hyperstimulation occurred, the cycle was cancelled and the patients were excluded from the study.
Methods:
Proper history taking including age, gravidity, parity, infertility duration, history of laparoscopic surgery, previous induction of ovulation in the last 6 months. Examination was done to assess weight, height (BMI), signs of androgen excess, thyroid gland and breast examination.
Serum FSH, LH, testosterone level, prolactin level and thyroid stimulating hormone on day 3 of spontaneous menstrual cycle were done. Serum Progesterone (P4) was done on day 22 (midluteal) to confirm ovulation if ≥ 10ng/ml.
Basal transvaginal U/S on day3 of the cycle to detect criteria of PCOS and count number of antral follicles in both ovaries and to exclude of any basal ovarian cyst. Transvaginal ultrasound was also used to follow follicular growth and endometrial thickness starting on day 8 and then every other day till assuming good ovulatory response when one or more follicles is ≥ 18mm and endometrial thickness ≥ 6mm.
Human Chorionic Gonadotropin (choriomon®, IBSA, Lugano, Switzerland) 10.000IU/I.M was administered when good ovulatory response was assumed. The intercourse was advised on the day of HCG injection and every other day for 4 days after injection HCG.
Number and size of Dominant follicles, endometrial thickness were recorded. Clinical pregnancy was detected by serum pregnancy test and by presence of intrauterine gestational sac with fetal pulsation.
Outcome measures: Primary outcomes was ovulation rate. Secondary outcomes were pregnancy rate.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Gharbia
-
Tanta, Gharbia, Egypt, 31111
- Ayman Shehata Dawood
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Infertility lasting one year or more in presence of regular intercourse,
- Patients' age between 20-35years
- Normal semen analysis according to WHO 2010
- Patent fallopian tubes (e) Normal prolactin and TSH.
- Anovulatory cycles confirmed by mid-luteal progesterone ≤ 3 ng/ml and
- Clomiphene citrate resistance for 3 cycles of 150mg.
Exclusion Criteria:
- Any hormonal disturbances eg. hyperprolactinemia,
- Immunological causes of infertility,
- Coital errors,
- Metabolic disorders and
- Poor patient compliance.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Letrozole
These patients were treated with letrozole (Femara®, Novartis New York, NY, USA) in a dose 2.5 mg (one tablet daily) orally began on the 3rd day to the 7th day of the cycle.
If ovulation is not achieved dose is increased by 2.5 mg in next cycle till 3 cycles.
|
These patients were treated with letrozole (Femara®, Novartis New York, NY, USA) in a dose 2.5 mg (one tablet daily) orally began on the 3rd day to the 7th day of the cycle.
If ovulation is not achieved dose is increased by 2.5 mg in next cycle till 3 cycles
|
Active Comparator: Gonadotropins
These patients were given urofollitropin (fostimon ®, IBSA, Lugano, Switzerland) in a dose of 75 IU/mL I.M from day 3rd to day 7th of the cycle beginning by one ampoule per day and the dose had been modulated according to response.
|
These patients were given urofollitropin (fostimon ®, IBSA, Lugano, Switzerland) in a dose of 75 IU/mL I.M from day 3rd to day 7th of the cycle beginning by one ampoule per day and the dose had been modulated according to response.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ovulation rate
Time Frame: 6 months
|
Number of mature follicles in each ovary>18mm
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pregnancy rate
Time Frame: 6 months
|
Number of pregnant women evidenced by serum HCG and gestational sac inside the uterus
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ayman Dawood, MD, assistant professor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- Study Protocol
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovulation Induction
-
Hue University of Medicine and PharmacyCompleted
-
Cognitive IVF a.s.University of Pecs; Brno University Hospital; Hospital General Universitario... and other collaboratorsRecruitingPoor Response to Ovulation InductionCzechia
-
Clínica EUGINCompletedPoor Response to Ovulation InductionSpain
-
The First Affiliated Hospital of Zhengzhou UniversityUnknownOvulation Induction | Clinical Pregnancy RateChina
-
CRG UZ BrusselMerck KGaA, Darmstadt, GermanyWithdrawnPoor Response to Ovulation Induction
-
UMC UtrechtFree University Medical CenterTerminatedin Vitro Fertilization | Ovulation InductionBelgium, Netherlands
-
Ain Shams Maternity HospitalRecruitingPoor Response to Ovulation Induction Poseidon Type IVEgypt
-
EMD SeronoCompletedInfertility | Ovulation Induction
-
Merck KGaA, Darmstadt, GermanyCompletedInfertility | Ovulation InductionSpain
-
Merck KGaA, Darmstadt, GermanyMerck, S.L., SpainTerminated
Clinical Trials on Letrozole 2.5mg
-
Fudan UniversityRecruitingEndometrial CancerChina
-
Novartis PharmaceuticalsCompletedBreast NeoplasmUnited States, Germany, Spain, United Kingdom, France, Austria, Russian Federation, Italy, Canada, Belgium
-
Mansoura University HospitalCompleted
-
Dartmouth-Hitchcock Medical CenterRecruitingBreast Cancer | ER Positive Breast CancerUnited States
-
National Taiwan University HospitalUnknownReproductive Techniques, Assisted | Investigative Techniques | Reproductive TechniquesTaiwan
-
Xiaojun ChenRecruitingObesity | Atypical Endometrial Hyperplasia | Endometrial Neoplasms | Progesterone ResistanceChina
-
Swiss GO Trial GroupHoffmann-La Roche; Novartis Pharmaceuticals; AGO Study Group; Anticancer Fund,... and other collaboratorsRecruitingFallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Neoplasm Epithelial | High-grade Serous Ovarian Carcinoma (HGSOC) | Low-grade Serous Ovarian Carcinoma (LGSOC) | Ovarian Endometrioid CarcinomaAustria, Switzerland, Germany
-
Beni-Suef UniversityCompleted
-
Xiaojun ChenRecruitingObesity | Atypical Endometrial Hyperplasia | Progesterone ResistanceChina